News

In October 2007, Galapagos announced an alliance agreement with Janssen providing Janssen with option rights to acquire worldwide, commercial licenses to novel small-molecules from up to 12 of

The collaboration combines Beactica’s unique approach to fragment-based drug discovery and GE Healthcare’s Biacore technology with enzymology expertise from Uppsala University, said Beactica. Under the terms of the

This approval strengthens the company’s position in the growing Asian market through direct entities and confirms its position as a global spine solution company, said LDR. LDR added

MaxGuard is claimed to be the first positive displacement needleless connector featuring impregnation of the antimicrobial additive into each of the components of the device. Laboratory testing has

The agency has completed its review of the response that Merck provided in July 2008 and has recommended that Merck submit additional data when the 48 month study

In this trial, which included an intensive diet and exercise behavior modification regimen, obese patients treated with Contrave, based on intent-to-treat and completer analyses, lost an average of

The Phase I proof of concept study compared intravenous CNS 7056 to placebo and a standard dose of midazolam, the current gold standard for procedural sedation. The anticipated

RGN-137 is a topical gel formulation of thymosin beta 4 peptide (Tâ4). The drug candidate was found to be safe and well-tolerated at all three dose levels, with

Under the terms of the proposal, each share of Exact Sciences would be exchanged for $1.50 in Sequenom common stock. This consideration would be subject to a floating